RenovoRx (RNXT) Return on Sales (2025 - 2026)

RenovoRx (RNXT) posted Return on Sales of 0.06% for Q1 2026, up 58.21% sequentially from 0.15% in Q4 2025, and up 11.0% YoY from 0.06% in Q1 2025.

RenovoRx (RNXT) Return on Sales (2025 - 2026) Analysis & Trends

RenovoRx has reported Return on Sales for 2 years, with the latest figure at 0.06% in Q1 2026.

Quarterly Return on Sales rose 11.0% year-over-year to 0.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.1% (changed N/A YoY) and the FY2025 annual result came in at 0.29%, up 617.0% from the prior year.
Return on Sales climbed to 0.06% in Q1 2026 per RNXT's latest filing, from 0.15% in the prior quarter.
Over five years, Return on Sales peaked at 0.06% in Q1 2026 and troughed at 0.17% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	140.01 Bn	132.16 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn	0.00%
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn	0.00%
4	Moderna	60.18 Bn	55.04 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.55 Bn	28.24 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.45 Bn	10.06 Bn	668.28 Mn	0.00%
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.19 Bn	26.36 Bn	-	0.00%
10	RenovoRx	61.49 Mn	61.49 Mn	766,000.00	-0.04%

Download Data